Modelling cancer progression using Mutual Hazard Networks
暂无分享,去创建一个
[1] C. Yeang,et al. Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Benjamin J. Raphael,et al. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer , 2015, Genome Biology.
[3] Jörg Rahnenführer,et al. Variable selection for disease progression models: methods for oncogenetic trees and application to cancer and HIV , 2017, BMC Bioinformatics.
[4] H Buerger,et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.
[5] Jack Kuipers,et al. pathTiMEx: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics , 2017, J. Comput. Biol..
[6] F. Markowetz,et al. Cancer Evolution: Mathematical Models and Computational Inference , 2014, Systematic biology.
[7] Jens Lagergren,et al. New Probabilistic Network Models and Algorithms for Oncogenesis , 2006, J. Comput. Biol..
[8] Nicholas Eriksson,et al. Conjunctive Bayesian networks , 2006, math/0608417.
[9] J. Lagergren,et al. Learning Oncogenetic Networks by Reducing to Mixed Integer Linear Programming , 2013, PloS one.
[10] Jack Kuipers,et al. Large-scale inference of conjunctive Bayesian networks , 2016, Bioinform..
[11] H. Akaike. A new look at the statistical model identification , 1974 .
[12] Niko Beerenwinkel,et al. Modeling Mutual Exclusivity of Cancer Mutations , 2014, RECOMB.
[13] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[14] Wayne R. Dyksen,et al. Efficient vector and parallel manipulation of tensor products , 1996, TOMS.
[15] W. Rathmell,et al. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy , 2009, Current oncology reports.
[16] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[17] Feng Jiang,et al. Inferring Tree Models for Oncogenesis from Comparative Genome Hybridization Data , 1999, J. Comput. Biol..
[18] Fabio Vandin. Computational Methods for Characterizing Cancer Mutational Heterogeneity , 2017, Front. Genet..
[19] Christopher A. Miller,et al. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors , 2011, BMC Medical Genomics.
[20] Jie Chen,et al. Gene expression in cardiac tissues from infants with idiopathic conotruncal defects , 2011, BMC Medical Genomics.
[21] Thomas Lengauer,et al. Learning Multiple Evolutionary Pathways from Cross-Sectional Data , 2005, J. Comput. Biol..
[22] A. Hanby,et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.
[23] J. Rahnenführer,et al. Cumulative disease progression models for cross‐sectional data: A review and comparison , 2012, Biometrical journal. Biometrische Zeitschrift.
[24] Peter Buchholz,et al. Structured analysis approaches for large Markov chains , 1999 .
[25] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[26] Giancarlo Mauri,et al. CAPRI: Efficient Inference of Cancer Progression Models from Cross-sectional Data , 2014, bioRxiv.
[27] Brian Schryver,et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.
[28] Martin Vingron,et al. Inferring the paths of somatic evolution in cancer , 2014, Bioinform..
[29] G. De Micheli,et al. Computer-Oriented Formulation of Transition-Rate Matrices via Kronecker Algebra , 1981, IEEE Transactions on Reliability.
[30] A. Schäffer,et al. The evolution of tumour phylogenetics: principles and practice , 2017, Nature Reviews Genetics.
[31] D. Cox. Regression Models and Life-Tables , 1972 .
[32] Nicholas Eriksson,et al. The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis , 2011, PloS one.
[33] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[34] Roded Sharan,et al. Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..
[35] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[36] Teresa M. Przytycka,et al. MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..
[37] Niko Beerenwinkel,et al. Quantifying cancer progression with conjunctive Bayesian networks , 2009, Bioinform..
[38] Michael Baudis,et al. Progenetix.net: an online repository for molecular cytogenetic aberration data , 2001, Bioinform..
[39] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[40] Niko Beerenwinkel,et al. TiMEx: a waiting time model for mutually exclusive cancer alterations , 2015, Bioinform..
[41] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[42] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[43] Jack Kuipers,et al. Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors , 2017, Genome research.
[44] Winfried K. Grassmann. Transient solutions in markovian queueing systems , 1977, Comput. Oper. Res..
[45] Benjamin J. Raphael,et al. Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data , 2015, J. Comput. Biol..
[46] G. Wahl,et al. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. , 2007, The international journal of biochemistry & cell biology.